STOCK TITAN

Eli Lilly (LLY) files Rule 144 notice to sell 305,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for Eli Lilly & Co (LLY) records a proposed sale of 305,000 shares of Common Stock through J.P. Morgan Securities LLC with an aggregate market value of $260,881,750 and an approximate sale date of 10/10/2025. The filing lists 946,456,759 shares outstanding for the class. The shares to be sold were acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust, showing an original acquired amount of 38,400,000 shares.

The notice also discloses multiple recent sales by Lilly Endowment Inc., including 280,000 shares sold on 07/24/2025 for $225,419,292 and a series of sales from 09/18/2025 through 10/09/2025 with individual proceeds reported. The signer certifies no undisclosed material adverse information and complies with Rule 144 procedural disclosure.

Positive

  • Sale disclosed under Rule 144 with broker identified (J.P. Morgan Securities LLC), supporting regulatory transparency
  • Aggregate market value provided ($260,881,750), giving clear investor-facing magnitude

Negative

  • Significant share disposition of 305,000 shares could increase free-float and near-term supply
  • Multiple recent sales by Lilly Endowment Inc. from 07/24/2025 through 10/09/2025 indicate ongoing dispositions

Insights

TL;DR: A routine Rule 144 notice detailing an affiliate sale of 305,000 LLY shares via a major broker on 10/10/2025.

The filing documents a proposed disposition under Rule 144 of 305,000 shares valued at $260,881,750, with the shares acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust. Using an established broker like J.P. Morgan Securities LLC and providing recent sale history helps satisfy the Rule 144 notice requirements and market transparency expectations.

Key dependencies include the seller meeting Rule 144 holding-period and notice conditions and the broker executing sales on or about 10/10/2025. Monitor reported sales volumes and dates; multiple recent disposals by Lilly Endowment Inc. through 10/09/2025 are documented, which may affect near-term free-float and trading liquidity.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the LLY Form 144 report?

It reports a proposed sale of 305,000 Eli Lilly common shares via J.P. Morgan Securities LLC with an aggregate market value of $260,881,750, planned on 10/10/2025.

Who is offering the shares for sale in this notice (LLY)?

The filing indicates the securities were held for the account of a person who received the shares by gift from the J.K. Lilly Sr. Trust on 02/10/1948.

How many LLY shares are outstanding according to the filing?

The filing lists 946,456,759 shares outstanding for the class.

Which broker is handling the proposed LLY sale?

The broker named is J.P. Morgan Securities LLC, located at 383 Madison Avenue, New York, NY.